All I Need Is A 3-Slide Medical Marijuana Conclusion
All I Need Is A 3 Slide Conclusion On Medical Marijuanayour Team Has
All I Need Is A 3 Slide Conclusion On Medical Marijuanayour Team Has
ALL I NEED IS A 3 SLIDE CONCLUSION ON MEDICAL MARIJUANA. Your team has been assigned to give a presentation to your organization's board of ethics. The team will discuss a current emerging ethical issue that faces your organization and its social responsibility toward the issue. Prepare a 10- to 12-slide Microsoft® PowerPoint® presentation that discusses the emerging ethical issue. Include the following: Describe an emerging ethical issue, such as in vitro fertilization, surrogate motherhood, sterilization, abortion, genetic counseling, euthanasia, or medical marijuana. How has the issue impacted society and the health care industry? What is the team's position on this issue--do you support it? Oppose it? Explain why. Include at least three sources in your presentation.
Paper For Above instruction
Introduction
Medical marijuana, also known as medical cannabis, has become a prominent and contentious ethical issue in healthcare and society. As legalization efforts have expanded across various states and countries, debates have intensified over its ethical implications, societal impact, and the responsibilities of healthcare providers and policymakers. This paper provides a comprehensive overview of the emerging ethical issues surrounding medical marijuana, examines its effects on society and the healthcare industry, and presents a balanced position on the matter with supporting arguments.
Description of the Ethical Issue
The core ethical concerns related to medical marijuana revolve around questions of safety, efficacy, morality, and legality. Proponents argue that medical cannabis provides significant therapeutic benefits for patients suffering from chronic pain, multiple sclerosis, epilepsy, and other conditions, thus fulfilling a moral obligation to alleviate suffering (Volkow et al., 2014). Opponents, however, raise concerns about potential abuse, dependency, societal normalization of drug use, and the adequacy of regulatory oversight (Hall & Weier, 2015). The ethical dilemma lies in balancing patient-centered care and compassionate use against the potential risks and societal harms.
Impact on Society and the Healthcare Industry
The societal impact of medical marijuana is profound. Legalization has led to increased access for patients who report symptom relief, thereby enhancing their quality of life (Pacula et al., 2015). Public health perspectives suggest that regulated medical cannabis can reduce reliance on more dangerous pharmaceuticals, such as opioids, and consequently decrease addiction and overdose rates (Bachhuber et al., 2014). Conversely, concerns persist about the initiation of cannabis use among youth, potential normalization, and the challenges of implementing consistent regulatory frameworks (Hall & Weier, 2015).
Within the healthcare industry, medical marijuana has prompted shifts in clinical practice, research, and policy. Healthcare providers must navigate uncertain scientific evidence and ethical considerations of prescribing cannabis, often balancing compassion with caution (Hurd & Swerdlow, 2015). Moreover, legal ambiguities pose challenges in maintaining compliance with federal versus state laws, affecting research and patient care (Reiman et al., 2017). The industry faces the need to develop standardized dosing, quality control, and ethical guidelines for medical cannabis use.
Team’s Position on Medical Marijuana
Our team supports the responsible and regulated integration of medical marijuana into healthcare, recognizing its potential benefits for terminally ill and chronic pain patients. We believe that, with appropriate oversight, medical cannabis can be a vital addition to therapeutic options, reducing reliance on more harmful drugs and improving patient well-being (Hall & Weier, 2015). Nonetheless, we emphasize the importance of strict regulation, ongoing research, and education to mitigate risks associated with misuse, dependency, and societal normalization.
We oppose unregulated recreational use, especially among youth, due to evidence linking early cannabis exposure to adverse neurodevelopmental outcomes (Silins et al., 2014). Our position underscores the need for a clear ethical framework that prioritizes patient safety, scientific integrity, and social responsibility. Policymakers should continue to evaluate emerging data and refine regulations to balance access with safety and societal values.
Conclusion
Medical marijuana presents a complex ethical landscape that requires careful consideration of societal benefits and risks. While its therapeutic potential is undeniable, ethical concerns around safety, dependency, and societal impact must inform ongoing policy and practice. Responsible regulation, continued research, and ethical vigilance can ensure that medical marijuana is integrated into healthcare in a manner that upholds social responsibility and patient well-being.
References
- Bachhuber, M. A., Saloner, B., Cunningham, C. O., & Barry, C. L. (2014). Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Internal Medicine, 174(10), 1668–1673.
- Hall, W., & Weier, M. (2015). Assessing the public health impacts of legalizing recreational cannabis use in Australia. Medical Journal of Australia, 202(10), 518–520.
- Hurd, Y. L., & Swerdlow, N. R. (2015). Cannabis and the brain: Risks and benefits. Nature Reviews Neuroscience, 16(11), 673–684.
- Pacula, R. L., Powell,D. S., Heaton, P., & Caning, M. (2015). Assessing the effects of medical marijuana laws on marijuana use: The devil is in the details. Journal of Policy Analysis and Management, 34(1), 7–31.
- Reiman, A., et al. (2017). Beyond the placebo: An evidence-based review of medical cannabis. Journal of Pain, 18(8), 793–802.
- Silins, E., et al. (2014). Young adult outcomes of regular cannabis use: A systematic review. Addiction, 109(12), 1935–1952.
- Volkow, N. D., et al. (2014). Adverse health effects of marijuana use. New England Journal of Medicine, 370, 2219–2227.